文献速递泌尿男性生殖肿瘤

CRLX101联合贝伐珠单抗对比标准治疗在晚期肾细胞癌的随机II期试验

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
PubMed 文献 · Ann Oncol · 2017-01-01

这项随机II期试验纳入既往接受过2-3线治疗的转移性肾细胞癌患者,1:1随机比较CRLX101联合贝伐珠单抗与标准治疗(研究者选择的未使用过的获批方案)。在透明细胞人群中,两组中位无进展生存期分别为3.7个月和3.9个月(分层log-rank P=0.831),客观缓解率分别为5%和14%(P=0.836),联合组未显示PFS改善。

要点

  • 在重度经治的透明细胞mRCC中,CRLX101联合贝伐珠单抗对比标准治疗未改善PFS。
  • 联合组与SOC组中位PFS分别为3.7个月与3.9个月(分层log-rank P=0.831)。
  • 联合组客观缓解率5%对比SOC组14%(Mantel-Haenszel检验P=0.836),无显著差异。

核心结论

  • 尽管早期Ib/2期试验显示 promising 疗效,本随机试验在重度经治的透明细胞mRCC中未证明CRLX101联合贝伐珠单抗对比获批药物改善PFS。
  • 该疾病领域不计划进一步开发。

研究设计与样本

  • 随机II期试验,纳入既往接受过2-3线治疗的转移性肾细胞癌患者,1:1随机分配至CRLX101联合贝伐珠单抗组或标准治疗组。
  • 标准治疗定义为研究者选择的任何未使用过的获批方案。
  • 共111例患者随机并接受至少1剂药物(CRLX101联合贝伐珠单抗组55例,标准治疗组56例)。
  • 主要终点为透明细胞mRCC患者经盲法独立放射学评估的PFS;次要终点包括总生存期、客观缓解率和安全性。

主要发现

  • 透明细胞人群中,CRLX101联合贝伐珠单抗组中位PFS为3.7个月(95%CI 2.0-4.3),标准治疗组为3.9个月(95%CI 2.2-5.4),分层log-rank P=0.831。
  • 经独立放射学评估的客观缓解率在CRLX101联合贝伐珠单抗组为5%,标准治疗组为14%(Mantel-Haenszel检验P=0.836)。
  • CRLX101联合贝伐珠单抗组合总体耐受良好,未发现新的安全性信号。

关键数值与推荐

  • 标准治疗组内患者接受的方案包括:单药贝伐珠单抗(19例)、阿昔替尼(18例)、依维莫司(7例)、帕唑帕尼(4例)、索拉非尼(4例)、舒尼替尼(2例)、替西罗莫司(2例)。

临床怎么用

  • 在重度经治的透明细胞mRCC患者中,CRLX101联合贝伐珠单抗对比标准治疗未显示PFS改善。
  • 该联合方案在本研究人群中总体耐受良好,未发现新的安全性信号。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101 + bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101 + bevacizumab versus standard of care (SOC) in refractory mRCC. PATIENTS AND METHODS: Patients with mRCC and 2-3 prior lines of therapy were randomized 1 : 1 to CRLX101 + bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. RESULTS: In total, 111 patients were randomized and received ≥1 dose of drug (CRLX101 + bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101 + bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0.831). The objective response rate by IRR was 5% with CRLX101 + bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101 + bevacizumab combination was generally well tolerated, and no new safety signal was identified. CONCLUSIONS: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101 + bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned. CLINICAL TRIAL IDENTIFICATION: NCT02187302 (NIH).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Voss MH, Hussain A, Vogelzang N, et al. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Ann Oncol. 2017. PMID: 28950297. doi:10.1093/annonc/mdx493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。